Evidence map›Paper›PMID 34583720›Full record

SynthesisJournal of cardiothoracic surgery2021

Systematic literature review evaluating evidence and mechanisms of action for platelet-rich plasma as an antibacterial agent.

Dalip Sethi, Kimberly E Martin, Sangeeta Shrotriya, Bethany L Brown

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cardiothoracic surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Frontiers in cellular and infection microbiology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Dalip SethiTerumo Blood and Cell Technologies, Inc., 10810 West Collins Avenue, Lakewood, CO, 80215, USA. dalip.sethi@terumobct.com.ORCID http://orcid.org/0000-0003-4308-0349
Kimberly E MartinBoulder Clinical Science, 302 Urban Prairie St., Fort Collins, CO, 80524, USA.
Sangeeta ShrotriyaServier Pharmaceuticals, 200 Pier 4, Boston, MA, 02210, USA.
Bethany L BrownAmerican Red Cross, Biomedical Services, Holland Laboratory, Rockville, MD, 20855, USA.
American Red Cross · USTerumo (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet rich plasma or PRP is a supraphysiologic concentrate of platelets derived by centrifugation and separation of whole blood components. Along with platelets and plasma, PRP contains various cell types including white blood cells (WBC)/leukocytes, both granulocytes (neutrophils, basophils, eosinophils) and agranulocytes (monocytes, lymphocytes). Researchers and clinicians have explored the application of PRP in wound healing and prevention of surgical wound infections, such as deep sternal wounds. We conducted this systematic literature review to evaluate the preclinical and clinical evidence for the antibacterial effect of PRP and its potential mechanism of action. 526 records were identified for screening. 34 unique articles were identified to be included in this literature review for data summary. Overall, the quality of the clinical trials in this review is low, and collectively qualify as Oxford level C. Based on the available clinical data, there is a clear trend towards safety of autologous PRP and potential efficacy in deep sternal wound management. The preclinical and bench data is very compelling. The application of PRP in treatment of wounds or prevention of infection with PRP is promising but there is a need for foundational bench and preclinical animal research to optimize PRP as an antibacterial agent, and to provide data to aid in the design and conduct of well-designed RCTs with adequate power to confirm antimicrobial efficacy of PRP in specific disease states and wound types.

Indexed as

Anti-Bacterial AgentsPlatelet-Rich PlasmaAnimalsSurgical Wound InfectionWound HealingAnti-Bacterial AgentsDeep sternal wound infectionPlatelet rich plasmaReviewSystematic literature searchWound infection

Identifiers

PMID34583720
PMCPMC8480088
OpenAlexW3202450794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.